🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,063 results for “BRIGHT MINDS BIOSCIENCES INC.” Clear

  1. Double Trouble in Recovery

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  2. Doxazosin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  3. Doxazosin 4mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    1 trial

  4. Doxazosin extended release

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine or Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  5. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule terminated

    2 trials

  6. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule active

    1 trial

  7. Dronabinol 120mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Smoking

    phase 2 small molecule completed

    1 trial

  8. Dronabinol 30mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  9. Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  10. Dynorphin 1 - 13

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  11. E-cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 other completed

    1 trial

  12. EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    2 trials

  13. EVP-6124

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule terminated

    1 trial

  14. Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  15. Enzalutamide

    BRIGHT MINDS BIOSCIENCES INC.

    Prostate Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  16. Everolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  17. Evolution: Young Women Taking Charge and Growing Stronger

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  18. Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 2 other active

    1 trial

  19. Extended-Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  20. FINGER 2.0 multidomain lifestyle-based intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Cognitive Decline

    phase 2 other active

    1 trial

  21. Family Therapy based on Structural Family Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  22. Flumazenil

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule completed

    1 trial

  23. Fluorodopa F 18

    BRIGHT MINDS BIOSCIENCES INC.

    Malignant Brain Neoplasm

    phase 2 small molecule active

    1 trial

  24. Fluoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources